KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
NCT06145139 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-11-22
Summary
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as a marker of subclinical residual disease and risk of recurrence.
Conditions
- Renal Cancer
Sponsors & Collaborators
-
University of Aarhus
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-01
- Primary Completion
- 2028-06-01
- Completion
- 2033-06-01
Countries
- Denmark
Study Locations
More Related Trials
-
Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT
NCT03616951 ·Status: UNKNOWN
-
Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors
NCT01544569 ·Status: COMPLETED
-
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
NCT04883827 ·Status: COMPLETED
-
NANOTECH RCC Biomarkers
NCT02923284 ·Status: COMPLETED
-
Studying Biomarkers in Samples From Younger Patients With Kidney Cancer
NCT01642095 ·Status: WITHDRAWN
-
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
NCT05079113 ·Status: COMPLETED
-
Circulating DNA in Surgically Treated NSCLC
NCT04037150 ·Status: UNKNOWN
-
Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer
NCT02718651 ·Status: COMPLETED
-
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
NCT00900276 ·Status: COMPLETED
-
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
NCT02499458 ·Status: COMPLETED
-
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
NCT06290856 ·Status: TERMINATED
-
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
NCT00908739 ·Status: WITHDRAWN
-
Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms
NCT01390597 ·Status: COMPLETED
-
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01576198 ·Status: COMPLETED
-
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
NCT03947346 ·Status: COMPLETED
-
Epidemiological Study on Malignancy Complicated With Renal Injury
NCT05392725 ·Status: UNKNOWN
-
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
NCT06202131 ·Status: RECRUITING
-
Renal Cell Carcinoma Microenvironment Discovery Project
NCT04005183 ·Status: COMPLETED
-
Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors
NCT01004783 ·Status: COMPLETED
-
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
NCT06339138 ·Status: ACTIVE_NOT_RECRUITING
-
Follow-Up Study of Kidney Cancer Patients
NCT00656955 ·Status: COMPLETED
-
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
NCT05853198 ·Status: RECRUITING ·Phase: NA
-
Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease
NCT02612350 ·Status: COMPLETED
-
DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer
NCT02079363 ·Status: UNKNOWN
-
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
NCT00899860 ·Status: TERMINATED